Group items matching

in title, tags, annotations or url

AAH Pharmaceuticals on Tuesday (November 15) announced the promotion of its commercial director David Bound to chief executive officer of the company. In his 10 years in the company, Mr Bound has helped to drive growth across the AAH business, implementing new digital channels for customers, and developing strategic partnerships with pharmaceutical manufacturers - drawing on from his vast experience in the healthcare industry, as well as in supply chain, operations, and trading. Commenting on his promotion, he said: "I'm delighted to be taking on this role at such a critical time for healthcare. There are many challenges affecting the industry right now - from inflationary pressures to workforce issues - and I'm looking forward to tackling them head-on alongside my excellent team."

The Pharmaceutical Services Negotiating Committee (PSNC) has refused to accept the Department of Health and Social Care (DHSC)'s decision to get rid of 'transitional payments' from February 2023. The pharmacy negotiator said that 'any reductions in payments at this point will be impossible for community pharmacy contractors to manage financially.' "We are also continuing to be clear with officials and ministers that CPCF funding needs an urgent uplift to help businesses to cope with soaring costs being driven by inflation and the workforce crisis. We put a comprehensive business case to the government for this uplift in the last CPCF negotiations." The latest 'transitional payments decision' by the Department follows the announcement last year that the value of the these payments would be phased down over the second half of 2022/23 and will be based on the latest monitoring and analysis of funding delivery. PSNC says it submitted a fully-costed bid for a 'Pharmacy First' service in its last round of negotiations alongside the case for an uplift to core CPCF funding. Both of these were refused.

Perrigo, one of the world's largest providers of self-care products has appointed Ronald van Workum as Sales Director Germany, Customer Strategy & Implementation DACH Cluster. van Workum will continue to drive the successful integration of HRA Pharma into the Perrigo network, with a focus on well-known brands such as Abtei, Compeed and Granu Fink. He most recently held the position of Head of Key Account Management for Perrigo in Europe, based in the Netherlands. Prior to joining Perrigo he worked for Procter & Gamble in several countries, including Singapore, and in various functions, including: Market Strategy Planning Manager for the Gillette brand; and in Europe as multifunctional Team Leader Emerging Channels. The company also announced Tobias Geiger has been promoted from his role as Finance Director of the Perrigo DACH Cluster, which he held since April 2020, to General Manager of the Perrigo DACH Cluster. During this time, he successfully supported the implementation and stabilisation of the DACH cluster. He also led several business optimisations with his teams, such as the implementation of SAP in Switzerland, process digitalisation and the creation of a DACH Finance business Partner Model. Before joining Perrigo, Geiger worked for Sanofi for more than 10 years in various leadership positions in DACH and in Latin America.

Positive Solutions is set to launch its new, innovative, cloud-based medicines management system - HxCare which will be showcased in October at the Care Show. HxCare will be free of charge to community pharmacies signing up to the HxCare Affiliate Programme (HxCAP) making it an ideal platform to support existing care home business and attract new ones. The cloud-based medicines management system aims to digitise workflows, reduce errors and free up care providers to spend more time delivering care to their residents. Designed to be truly mobile, HxCare will be tablet based and has been developed by working closely with both care homes across the sector and their pharmacy partners who relish the prospect of an eMAR solution that integrates into their Analyst PMR. It is one of five new products being launched by Positive Solutions on the Hx platform this year. HxConsult is already live supporting pharmacies looking to maximise their service revenue. HxIntel will deliver real-time dashboards, reports and insights into the performance of pharmacy businesses of all sizes. My Health Hub will revolutionise patient pharmacy relationships whilst HxDispense is set to be the ultimate next generation PMR system. This modular, cloud-based interoperable ecosystem takes healthcare technology to a new level.

There has been extensive national media coverage today (August 11) on how medicine shortages have forced patients to visit multiple pharmacies to get their prescriptions filled or return to their GP to be prescribed alternative drugs. These media reports have been based on a survey involving more than 1,500 pharmacists in the UK, in which over a half of those polled said that their patients' health had been put at risk in the last six months. In response to a query from Pharmacy Business, the Department of Health and Social Care (DHSC) said it monitors the medicines supply chain closely to prevent any shortages and acts swiftly when any issue arises. A DHSC spokesperson told Pharmacy Business: "We take patient safety extremely seriously and we routinely share information about medicine supply issues directly with the NHS so they can put plans in place to reduce the risk of any shortage impacting patients, including offering alternative medication.

HRA pharma has announced the resignation of David Wright who moves on after serving the company for more than five years as chief executive officer. The company has appointed Martyn Hilton, chief commercial officer for HRA Pharma, as interim CEO effective from September 1, 2022. David helmed the company during a period of transformation and set the course for its tremendous growth, elevating HRA Pharma into a leading provider of over-the-counter self-care products. He commented: "Given the significant progress HRA has made, along with my personal goals after leading HRA for more than five years, I believe now is the time to step away from the business. "I am proud of all that we have accomplished, making HRA well-known for its Women's Health, Wound Care and Scar Care leadership, operating via brands including ellaOne, Hana, Compeed and Mederma. I appreciate all the team members involved in the success of the organization and believe Perrigo and HRA are well-positioned to elevate this business and these brands to the next level."

Essential Pharma, an international speciality pharma group, has procured an establishment and manufacturing licences in Switzerland and Malta. Following a successful inspection by Swissmedic, the company has been granted an establishment licence in Switzerland, which will allow the company to significantly enhance its supply chain efficiency for a wide range of important medicinal products. It will apply to transactions for both finished and unfinished pharmaceuticals, allowing importing, exporting, wholesaling and trading abroad. Essential Pharma has also received a manufacturing and importation authorisation (MIA) in Malta, following a successful Good Manufacturing Practice (GMP) inspection by the Malta Medicines Authority. The MIA will allow the company to import medicinal products into the European Union where manufacturing has taken place in a third country. This will allow greater flexibility in how the business manages the flow of medicines across its territories. These approvals strengthen the company's geographical expansion, improve its operational efficiencies, and enhance its offering as a global business partner. They will also provide new strategic opportunities for the company and will play a fundamental role in driving value creation through functional improvements to scale and productivity.

In a mutual agreement with the STADA board, Roger Scarlett-Smith has stepped down from his role as head of UK. The company has assigned the responsibility of UK operation to Rudolf Bär with current responsibilities as cluster head for Mid-Sized European Markets. Scarlett-Smith joined STADA in October 2018 to lead the UK operation upon the retirement of Dieno George. Prior to this, he had enjoyed an illustrious career in the Consumer Healthcare sector, largely with GlaxoSmithKline, for which he held positions including as President North America, President EMEA and Head of Global Categories. Under his leadership, the STADA UK business has grown sales by 50 per cent and profitability has more than doubled. He has reshaped the business to improve efficiency. There has been a marked acceleration of product innovation including key line extensions to the Zoflora disinfectant range as well as the introduction of a salmeterol and fluticasone inhaler in the Rx respiratory sector. Meanwhile, T+R has developed a fine reputation regionally, being voted number 1 regional company last year and winning many national industry awards.

If you have been injured on someone else's property, you may be wondering what evidence is needed to win your case. Property owners are responsible for ensuring that their premises are safe for visitors, and if they fail to do so, they can be held liable for any injuries that occur. In this blog post, we will discuss the types of evidence that may be necessary to prove your case and win financial compensation for your injuries. 1) DUTY OF CARE The first piece of evidence that you will need to prove your case is that the property owner owed you a duty of care. This means that they were required to take reasonable steps to keep you safe from harm while you were on their property. If the property owner did not live up to this duty, and you were injured as a result, they can be held liable according to Carpenter & Zuckerman lawyers. To prove that the property owner owed you a duty of care, you will need to show that you were an invitee or licensee on the property. Invitees are people who are invited onto the property for business purposes, such as customers or delivery people. Licensees are people who are allowed onto the property for non-business reasons, such as social guests. If you were not an invitee or licensee, the property owner may not be held liable for your injuries.

Anyone who has studied the finances of an independent pharmacy business knows that money is tight. In many cases, they are perilously close to failure. It's easy to assume they are retail businesses, cashing in on the higher public profile the sector has enjoyed during the pandemic years. But those have been mere words. Certainly, the pandemic represented a halcyon period for the profession. We engendered a feeling of normality, dependable and accessible to society. We played a substantive role in keeping people out of hospitals and giving the vulnerable the ability to live independently from their own homes for longer. We mobilised to smash flu vaccination records and deliver covid jabs. But despite the warm words of a new service based future and the incessant expressions of gratitude contractors desperately need the headroom to prepare, plan and invest. Platitudes, press releases and assurances of a bright clinical future are small comfort to what is needed and that's cash on the table. As the adage goes: "Talk is cheap, money buys houses." Cashflow crisis Since 2016, we have witnessed almost 650 pharmacies fall by the wayside. Some may have merged; the majority, however, have perished due to the relentless need for an increasing cashflow. It is cash, or rather the lack of it, which is killing independent pharmacies.

In his maiden speech delivered to community pharmacy since becoming new minister with responsibility for the sector, Will Quince MP said he's determined to be "your champion" and "voice in government". Addressing delegates on Wednesday (Oct 12) as chief guest at the 22nd Pharmacy Business Awards in central London, he praised community pharmacy for delivering 25 million Covid-19 vaccines, five million flu jabs, 200 million lateral flow testing kits and millions of medicines throughout the pandemic. "These local efforts became the national success story," he told over 600 attendees at a gala dinner held at the iconic Park Plaza Westminster Bridge hotel overlooking the Houses of Parliament. 'We need you now' Quince, who was appointed minister of state at the Department of Health and Social Care on 7 September 2022, added: "Just as we needed you in the pandemic, we need you now," highlighting the vital role of community pharmacy in realising the secretary of state (Thérèse Coffey)'s vision, particularly in regard to her much talked about 'Plan for Patients'.

Rosemont Pharmaceuticals (Rosemont) has acquired Lucis Pharma Ltd, a specialist pharmaceutical business in the UK. Through this acquisition Rosemont will expand its existing portfolio and have access to a pipeline of innovative products, providing lifesaving pharmaceuticals to the UK and overseas markets. Founded in 2012, Lucis has grown to become a leading provider in the development and licensing of novel and exclusive medicines. With over a dozen SKUs covering a variety of therapeutic areas, Lucis has established a strong portfolio that, in addition to a pipeline of innovative developments, serve the growing patient need for liquid medicines. The acquisition will enable Rosemont to broaden its portfolio and enter the unit dose / sachet market through the pipeline products, whilst growing the business through recent Lucis product launches in 2021/22. "As well as continuing to broaden our portfolio and add to our strong growth globally, this acquisition also gives access to pipeline products and developer relationships to accelerate our entry into new product areas such as sachets" said Howard Taylor, Chief Executive Officer of Rosemont.

A pharmacy group operating in London and the surrounding areas has said it's cliched a financial deal worth £4.25 million with a major global bank to bolster its mergers and acquisitions activity. Osbon Pharmacy Group said on Monday (19 June) that it would use the multi-million-pound funding package from HSBC UK to also invest in bringing accessible and comprehensive medical services closer to the doorstep of Londoners and people of South East England. The family-run business said the new money will open new position which will include opportunities for pharmacists, pharmacy assistants, pharmacy technicians, dispensers, accounts clerks and delivery drivers, taking the company's total headcount to 185. The group, which currently has 26 pharmacies across London and South East England, was established in 2005. The company offers a range of medicine and prescription services as well as offering customary help and advice. It switched to banking with HSBC UK last year as part of a £6.9M refinance package, which saw the business acquire nine pharmacies and takes the total funding provided by HSBC UK to date to £11.1m.

Stone Pharmacy in Barnsley, South Yorkshire has been sold to existing operator, Livesey Healthcare, which owns another pharmacy in East Lancashire for an undisclosed price. Stone Pharmacy is a well-established, 100-hour community pharmacy that is run under full management with a locum Pharmacist, and dispenses an average of 22,000 items per month. The business adjoins Garland House surgery in the South Yorkshire village of Darfield, which is circa six miles east of Barnsley and circa 14 miles north of Sheffield. The pharmacy has been owned by experienced operators, Khuram Akhtar and Mohammed Ali, trading as MEDS2U Ltd, for the last seven years, and was recently brought to market to allow the pair to pursue new ventures both in and out of community pharmacy. Khuram Akhtar, former owner of Stone Pharmacy, commented: "The business at Stone Pharmacy has been a fantastic enterprise for many years for us, with limited competition and a position central to the local community we have always enjoyed the support of the nearby population and are pleased that it is now in the hands of experienced operators who can build on that foundation with the expansion of new services.

Community pharmacies are located within the very hotspots of peoples' communities, yet a staggering 720 individual businesses have stopped trading since 2015. It has been called a "national disgrace and a betrayal to the elderly and the vulnerable" by sector leaders. The funding crisis has been compounded by a gruelling 18-24 months post-Covid, both have which have placed immense pressure on the retail pharmacy sector. The population is aging and with this comes patients living with a range of long-term health conditions. Medication regimes are becoming ever more complex and as a result, maintaining prescription and medication adherence services is challenging to say the least. Yet the public feel great warmth towards their local pharmacy businesses, and this positive attitude only increased during the pandemic. In fact, in a recent report launched by Omnicell on the Changing Role of the Pharmacist, a survey of public opinion found that a third (32 per cent) said they perception of their local pharmacy had changed for the better since the start of the pandemic and nearly half (44 per cent) said they are more familiar with their local pharmacy services since the start of COVID. This has meant that the role of the pharmacist has also changed and evolved; in part due to a national need and drive for more patients to be seen and supported clinically by pharmacists. This change of service provider role has slowly been developing over the last couple of years. Pharmacists are currently carrying out 65 million consultations a year - a staggering rise of 44 per cent in the last 24 months alone.

Community Pharmacy England (CPE) to host a Parliamentary drop-in event in July to brief MPs and Peers about the ongoing medicines supply chain issues that are negatively affecting pharmacies and their patients across the country. CPE's Pressures Survey earlier this year highlighted the extent of both the operational and financial impacts of medicines supply issues on pharmacy businesses, therefore it has continued to hear from both pharmacy owners and others about the problems. The event aims to ensure that MPs understand the problems and their impact on pharmacies. Peter Dowd MP is hosting the event, joined by representatives from Community Pharmacy England, the Nuffield Trust, patient groups and more. The event will also be another opportunity to talk to MPs from across the political spectrum about the very serious situation that community pharmacies still find themselves in and the need for further investment in the sector. Janet Morrison OBE, Chief executive of Community Pharmacy England said: "The results of our Pressures Survey earlier this year showed just how much supply issues are continuing to negatively impact pharmacy businesses and all those who work in them. The survey found that almost all pharmacy owners (97%) are facing significant increases in wholesaler and medicine supply issues, with 71% saying this was leading to delays in prescriptions being issued.

French drugmaker Sanofi will make 30 of its treatments, including insulin, available on a not-for-profit basis in 40 lower-income countries in the first step of its plan to increase access to its medicines worldwide. The treatments will be provided under the new Impact brand, part of Sanofi's global health unit launched last year, which sits outside the commercial business. The plan also includes the $25 million Impact fund, which will go towards supporting local start-up healthcare businesses and providing training on using the medicines, Sanofi said. "There's a lot of noise at the moment from different companies jumping into this space… but investing in entrepreneurship, in the ecosystem, is a new thing," said Jon Fairest, who heads the global health unit. The treatments available are on the World Health Organization's essential medicines list, and insulin in particular has been singled out by the UN agency as a life-saving medicine for diabetics that is difficult to access in many lower-income countries, where the burden of disease is growing.

The Pharmacists' Defence Association has called on the Scottish government to end unnecessary pharmacy closures and introduce emergency regulations to force companies that operate Scotland's pharmacies to open on the days and hours they have agreed. It is concerned that decisions made by some health boards in Scotland have now allowed pharmacy owners to close their pharmacies on Saturdays. The PDA is worried that a pharmacy closure could have negative impact on patients and other parts of the NHS, including neighbouring pharmacies, addiction and mental health services, and minor injury and A&E units. The association claims that there are record numbers of registered pharmacists who are available to work and therefore a decision to close a pharmacy over staff shortages is misleading. "The business owners may claim there is a shortage of pharmacists, but when they actively cancel agreed hours of work it does not suggest there is a shortfall of workers," said the PDA, adding: "These business decisions often include closing their pharmacies at very short notice, even when pharmacists are available and willing to work."

During the coronavirus pandemic many people found themselves working from home, and this has continued to some extent in many businesses. A change in working environment can bring challenges, one of which can be joint pain and discomfort. Imagine you have gone from a busy office environment, meeting in boardrooms and visiting the canteen for a coffee, to working at home on your dining room table, walking several feet to get a cup of tea and sitting back down again, this change in surroundings can have an impact on your joints. Community pharmacists can be a source of knowledge to help individuals that may be suffering from joint complaints, this may be from the above scenario or just general aches and pains that come from an office based role. Firstly, it's important for us to know the effects of sitting down at a desk all day (not a scenario I'm sure many community pharmacists experience daily): Back pain - is one of the most common complaints. This can be caused by bad posture while sitting too high, too low, or hunched over. While this may present as just a soreness or discomfort, if not rectified and/or accessed this can lead to some serious health issues such as spinal compression, sciatica or spinal stenosis.

It was a night filled with anticipation and excitement, and the atmosphere was electric with a sense of achievement and pride. The 23rd annual Pharmacy Business Awards had the honour of hosting the distinguished Shadow Secretary of State for Health and Social Care, Wes Streeting, who served as the event's chief guest. The event took place on 4 October at the Park Plaza Westminster Bridge, located on the South Bank of the River Thames, right across from the Houses of Parliament. There was a gathering of 600 guests, impeccably attired by the dress code, which added to the festive atmosphere. In his keynote speech, Labour MP Streeting said the NHS, which marked its 75th anniversary in July, could once again become the "envy of the world".